Gil T - Search Results

1

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A. Aftimos P, et al. Among authors: gil t. Eur J Cancer. 2016 Jun;60:117-24. doi: 10.1016/j.ejca.2016.03.010. Epub 2016 Apr 20. Eur J Cancer. 2016. PMID: 27107326 Clinical Trial.

2

Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.

Freyer G, Hennebert P, Awada A, Gil T, Kerger J, Selleslags J, Brassinne C, Piccart M, de Valeriola D. Freyer G, et al. Among authors: gil t. Clin Cancer Res. 2002 Jan;8(1):95-102. Clin Cancer Res. 2002. PMID: 11801544 Clinical Trial.

3

Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.

Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, Moerman C, de Valeriola D, Piccart MJ. Awada A, et al. Among authors: gil t. Anticancer Drugs. 2004 Jun;15(5):499-502. doi: 10.1097/01.cad.0000127331.29310.8a. Anticancer Drugs. 2004. PMID: 15166625 Clinical Trial.

4

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M. Awada A, et al. Among authors: gil t. Br J Cancer. 2005 May 23;92(10):1855-61. doi: 10.1038/sj.bjc.6602584. Br J Cancer. 2005. PMID: 15870716 Free PMC article. Clinical Trial.

5

Will the dark sky over advanced renal cell carcinoma soon become brighter?

D'Hondt V, Gil T, Lalami Y, Piccart M, Awada A. D'Hondt V, et al. Among authors: gil t. Eur J Cancer. 2005 Jun;41(9):1246-53. doi: 10.1016/j.ejca.2004.11.025. Eur J Cancer. 2005. PMID: 15939260 Review.

6

[Kidney cancer: from biology to clinical medicine].

Lalami Y, Gil T, D'Hondt V, Piccart M, Awada A. Lalami Y, et al. Among authors: gil t. Rev Med Suisse. 2006 Mar 1;2(55):600-4, 606-8. Rev Med Suisse. 2006. PMID: 16562604 Review. French. No abstract available.

7

Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.

Kasper B, Lossignol D, Gil T, Flamen P, De Saint Aubain N, Awada A. Kasper B, et al. Among authors: gil t. Anticancer Drugs. 2006 Nov;17(10):1223-5. doi: 10.1097/01.cad.0000231486.94191.65. Anticancer Drugs. 2006. PMID: 17075323

8

Novel treatment strategies for soft tissue sarcoma.

Kasper B, Gil T, D'Hondt V, Gebhart M, Awada A. Kasper B, et al. Among authors: gil t. Crit Rev Oncol Hematol. 2007 Apr;62(1):9-15. doi: 10.1016/j.critrevonc.2006.11.008. Epub 2006 Dec 1. Crit Rev Oncol Hematol. 2007. PMID: 17141519 Review.

9

A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.

Awada A, Zhang S, Gil T, de Valeriola D, Lalami Y, De Porre P, Piccart-Gebhart MJ. Awada A, et al. Among authors: gil t. Curr Med Res Opin. 2007 May;23(5):991-1003. doi: 10.1185/030079907x178810. Curr Med Res Opin. 2007. PMID: 17519066 Clinical Trial.

10

Molecular targeted therapies in breast cancer: where are we now?

Widakowich C, de Azambuja E, Gil T, Cardoso F, Dinh P, Awada A, Piccart-Gebhart M. Widakowich C, et al. Among authors: gil t. Int J Biochem Cell Biol. 2007;39(7-8):1375-87. doi: 10.1016/j.biocel.2007.04.015. Epub 2007 May 4. Int J Biochem Cell Biol. 2007. PMID: 17543572 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters